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SHORT COMMUNICATION
Small molecules targeting glycogen synthase kinase 3 as potential drug
candidates for the treatment of retinitis pigmentosa
Miguel Marchenaa, Beatriz Villarejo-Zoria, Josefa Zaldivar-Diezb, Valle Palomob, Carmen Gilb,
Catalina Hernandez-Sancheza, Ana Martınezb and Enrique J. de la Rosaa
aDepartment of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas (CSIC), Madrid, Spain; bDepartment of Chemical and
Physical Biology, Centro de Investigaciones Biologicas (CSIC), Madrid, Spain
ABSTRACT
Retinitis pigmentosa (RP) is an inherited retinal dystrophy that courses with progressive degeneration of
retinal tissue and loss of vision. Currently, RP is an unpreventable, incurable condition. We propose glyco-
gen synthase kinase 3 (GSK-3) inhibitors as potential leads for retinal cell neuroprotection, since the retina
is also a part of the central nervous system and GSK-3 inhibitors are potent neuroprotectant agents. Using
a chemical genetic approach, diverse small molecules with different potency and binding mode to GSK-3
have been used to validate and confirm GSK-3 as a pharmacological target for RP. Moreover, this medicinal
chemistry approach has provided new leads for the future disease-modifying treatment of RP.
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Introduction
Retinal neurodegenerative diseases like age-related macular
degeneration, glaucoma, diabetic retinopathy and retinitis pigmen-
tosa (RP) are disorders that have different etiology and pathogen-
esis and where the progressive impairment of diverse retinal cell
types leads to vision loss. However, at the cellular and molecular
level, the response to retinal injury is similar in all of them, and
results in morphological and functional impairment of retinal cells.
Interestingly, an inflammatory response, oxidative stress and acti-
vation of apoptotic pathways are common features in all these
diseases1. Altogether they represent a major cause of blindness
and a public health challenge. Up to date, there is not effective
treatment for their neurodegenerative component, although many
lines of basic research are devoted to identify their basic path-
ology and to develop effective treatments2.
Among other retinal degenerative disorders, RP and glaucoma
course with neuronal death of photoreceptors and retinal ganglion
cells, respectively. RP, together with other inherited retinal dystro-
phies, comprises a genetically heterogeneous, although clinically
similar, group of neurodegenerative retinal disorders caused by
mutations in more than 250 different genes. These genetic defects
disrupt the function of photoreceptor cells which gradually causes
night blindness, progressive constriction of the visual field and
eventually blindness3. The progression of visual loss rate varies
within individuals. Most people with RP are legally blind by the
age of 40. RP is categorized as a rare disease, with a prevalence
reported of one case out of the 3000–4000 individuals4.
The retina is a highly specialized sensory tissue that belongs to
the central nervous system. It may be considered as an accessible,
external part of the brain, as both derive from the most rostral
neural tube5. In fact, the retina and the rest of the central nervous
system share identical physiological and pathological molecular
pathways. Consequently, diseases of the brain and the retina show
similarities. For example, neuroinflammation appears as a relevant
process for retina and brain neurodegenerative diseases1,6 and
may provide a promising target when looking for therapeutic
treatments for the central nervous system in general, and for the
retina in particular7.
Glycogen synthase kinase 3 (GSK-3) is a constitutively active
Ser/Thr kinase ubiquitously expressed in the human body.
Although it was first identified as an enzyme involved in glycogen
synthesis8, its involvement in the regulation of multiple physio-
logical functions has been well-characterized. GSK-3 has been
categorized as a central kinase in a large number of prevalent dis-
eases such as psychiatric and neurodegenerative diseases, diabetes
and cancer9. Inflammation has been postulated as a link for all
these diseases-mediated by GSK-3 malfunction10. The recent dis-
covery of cellular location of GSK-3 in retina, both in M€uller and
photoreceptor cells11, led to recently propose GSK-3 as a key
player in retinal neuronal death both in early diabetic retinopathy
and retinal ischemic injury12,13. Moreover, lithium which among
many different targets is a weak GSK-3 inhibitor (IC50¼2mM) has
been used to reduce intraocular pressure in a rat model of glau-
coma when it was intraperitoneally administered14. Additionally,
valproic acid, that has been reported as an indirect inhibitor of
GSK-3 through direct inhibition of histone deacetylase15, showed a
short-term benefit for RP patients16,17, although the mechanism
underlying this effect is not well-understood18.
Based in our previous experience with GSK-3 inhibitors as drug
candidates for neurodegenerative disorders19, and in the search
for RP therapies, our goal is to study whether GSK-3 inhibitors
could be systemically administered as a potential therapy for RP.
In this communication, we report ex vivo studies that show the
potential of GSK-3 inhibitors to protect retinal cells and, thus, their
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potential to be translated into treatments to delay vision loss, par-
ticularly in RP.
Methods
Chemistry
Compounds 1, 2 and tideglusib have been synthesized in our lab-
oratories following their previous described procedures20.
Biology
Animals
The rd10 mouse model of RP is a homozygous recessive mutant
for phosphodiesterase 6b (Pde6brd10/rd10) on a C57BL/6J back-
ground. It was kindly provided by Bo Chang from The Jackson
Laboratory (Bar Harbor, ME). Wild type (WT) control mice of the
same background were obtained from The Jackson Laboratory. All
animals were housed and handled in accordance with the ARVO
statement for the use of animals in ophthalmic and vision
research, European Union guidelines, and those of the local ethics
committees of the CSIC and the Comunidad de Madrid. Mice were
bred in the CIB core facilities on a 12/12-h light/dark cycle.
Retina explant cultures
P23 rd10 and P42–43WT mice were euthanized, and their eyes
were enucleated. Retinas were dissected and cultured on Teflon
filters in R16 medium as described21 (See also Figure 2). For the
glaucoma model, WT retinas were treated with 50mM NMDA dur-
ing 48 h, with a medium change after 24 h. The rd10 mouse retinas
were cultured for 24 h. Compound 1 was employed at 3.2mM,
compound 2 at 10 mM and tideglusib at 10 mM. Retinas were sub-
sequently fixed in 4% (wt/vol) paraformaldehyde in phosphate
buffer 0.1 M, pH 7.4 for 1 h at RT and processed for the detection
of cell death.
Cell death visualization and counting
Ganglion cell and photoreceptor cell death was visualized by DNA
fragmentation assay terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end labeling (DeadEnd Fluorometric TUNEL sys-
tem; Promega, Madison, WI) as described22. After labeling, the
retinas were mounted in Fluoromount-G (Southern Biotechnology,
Birmingham, AL), stained with DAPI, and analyzed on a laser con-
focal microscope (TCS SP5; Leica, Microsystems, Wetzlar, Germany).
Image acquisition was performed in four areas of each retina.
Serial optical sections were acquired in the depth of the ganglion
cell layer or the outer nuclear layer, as determined in z-axis retinal
sections, to ensure that TUNEL-positive nuclei belong to ganglion
cells or to photoreceptors, respectively. Direct counting of TUNEL-
positive cells was carried out on merged images using ImageJ
v1.48.s software. Paired statistical analysis was performed using
the Wilcoxon signed-rank test.
Results and discussion
In order to confirm the therapeutic relevance of GSK-3 modulation
on retinal pathologies, we employed a chemical genetic approach
in ex vivo studies. The chemical genetic rationale postulates that
different small chemical probes assayed in different in vitro, ex
vivo and/or in vivo studies contribute to decipher the role of a
potential therapeutic target23. Consequently, here we selected
three chemically diverse small heterocyclic molecules designed
and synthetized in our laboratory that target GSK-3 by different
mechanism of inhibition (Figure 1): a substrate competitive inhibi-
tor with an iminothiadiazole scaffold1,24 an ATP competitive inhibi-
tor belonging to the maleimide heterocyclic family2,25 and
tideglusib, a non-ATP, non-substrate competitive GSK-3 inhibitor
Figure 2. Organotypic culture design. (A) The retinas were mounted with the photoreceptors in direct contact to the Teflon disc. (B) After extraction from the eyeball,
four cuts were made in the retina to facilitate attachment. Two retinas were cultured in each well.
Figure 1. Chemical structures of the selected candidates and their GSK-3 inhibition features.
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currently in clinical trials for autism spectrum disorders26.
Tideglusib is a thiadiazolidindione (TDZD) and currently the most
advanced compound in clinical development among the selected
GSK-3 inhibitors. Additionally, 1, 2 and Tideglusib have previously
been tested in cell cultures and animal models showing no
toxicity27–30.
First we assayed the two more novel inhibitors (1 and 2) in ret-
inal explants obtained from rd10 and cultured over Teflon discs
(Millipore), as exemplified in Figure 2.
The rd10 mouse retinal explants are a RP disease model in
which there is intrinsic photoreceptor cell death. The retinas were
dissected at postnatal day P23, at the peak of cell death31, and
cultured in the absence or presence of compounds 1 and 2. Cell
death was visualized by TUNEL and quantified. Both GSK-3 inhibi-
tors significantly reduced photoreceptor cell death (Figure 3) eli-
cited a neuroprotective action in the RP model. Further, they
suggest a novel potential role of GSK-3 inhibition on the treat-
ment of this retinal pathology.
Next, the retinal explants were obtained from wild type (WT)
mice and cultured as above in the presence of N-methyl-D-aspar-
tate (NMDA)32, a glutamate receptor agonist. This excitotoxic treat-
ment mimics glaucoma-related damage of the retinal ganglion
cells and has been used to validate the potential of GSK-3 inhibi-
tors in retinal cells protection.
NMDA treatment induced massive cell death in the ganglion
cell layer that was significantly reduced when the retinas were co-
incubated with either one of the two GSK-3 inhibitors (Figure 4).
These results confirmed the neuroprotective effect of GSK-3 inhib-
ition in retinal tissue, since the two pharmacological probes, with
different chemical scaffolds but with the common property of
being selective GSK-3 inhibitors, reduced significantly retinal cell
death33.
Finally, we confirmed the pro-survival effect of GSK-3 inhib-
ition in the RP model with a third GSK-3 inhibitor, tideglusib.
This compound has a chemical scaffold different to the other
two inhibitors described above (compounds 1 and 2) and shows
a non-ATP, non-substrate competitive mechanism of GSK-3
inhibition. The treatment of rd10 mouse retinal explants with
tideglusib significantly reduced photoreceptor cell death (Figure
5), an observation that reinforces the role of GSK-3 as pharma-
cological target in retinal RP neuroprotection. Further, it opens
an interesting translational opportunity. Tideglusib is an oral
drug that has shown a wide safety window in human clinical
trials both in Alzheimer’s disease and progressive supranuclear
palsy34, and it is currently on clinical trials for autism spectrum
disease26. In the light of the results described here, we propose
the use of tideglusib for the treatment of retinal diseases, such
as RP.
Conclusions
During the last years a large body of evidence shows that GSK-3
pathway is altered in neurodegenerative conditions of the central
nervous system and small molecules targeting GSK-3 selectively
have been developed as disease-modifying drugs for several
unmet diseases. However, the role of GSK-3 inhibitors in retinal
pathologies has not been extensively studied although they may
represent potential therapeutic candidates for retinal degeneration
therapy. Hereby, we have shown that GSK-3 inhibition results in a
protection of retinal ganglion cells and photoreceptor cells, an
observation made with three different inhibitors in two different
ex vivo models of retinal pathologies, including RP. The use of
mechanistically and structurally diverse GSK-3 inhibitors allows us
to state that the neuroprotective effect was produced by the tar-
get inhibition, highly reducing the possibilities of cross-reactivity
based on the structure or inhibition type. The results of these
studies suggest that GSK-3 inhibitors are a potential pharmaco-
therapeutic strategy to rescue photoreceptor cells, as well as ret-
inal ganglion cells, from a progressive degeneration such the one
present in RP. Furthermore, results obtained upon tideglusib treat-
ment in the rd10 model leads us to propose this compound as a
clinical lead for RP.
Finally, the transient benefit observed in RP patients after
oral intake of indirect GSK-3 inhibitor valproic acid, suggests
and supports the clinical therapeutic potential of GSK-3 inhibi-
tors for the treatment of RP. Together with the results here
Figure 3. GSK-3 inhibitors decreased photoreceptor cell death in rd10 mouse retinal explants. Representative images of groups (A) vehicle, (B) treatment with com-
pound 1 and (C) treatment with compound 2. D–E. Graphic representation of data: (D) mean± standard error is represented for each experimental group. The number
in brackets corresponds to the number of retinas; (E) Individual retinal values are depicted. Significances were calculated with t student test : p< 0.01,: p< 0.001.
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shown, selective GSK-3 modulation emerges as a new thera-
peutic target for the treatment of RP, opening new lines of
research to discover an effective pharmacotherapy for RP and
other retinal diseases.
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